Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma.

Journal of neuro-oncology - 1 Jun 2024

Yamamura Toshihiro, Tamura Kaoru, Kobayashi Daisuke, Inaji Motoki, Toyama Yuka, Wakimoto Hiroaki, Kiyokawa Juri, Hara Shoko, Tanaka Yoji, Nariai Tadashi, Shimizu Kazuhide, Ishii Kenji, Maehara Taketoshi

Abstract excerpt

PURPOSE: The proximate localization of MTAP, which encodes methylthioadenosine phosphorylase, and CDKN2A/B on Chromosome 9q21 has allowed the loss of MTAP expression as a surrogate for homozygous deletion of CDKN2A/B. This study aimed to determine whether MTAP status correlates with clinical outcomes and 11C-methionine uptake in astrocytomas with IDH mutations. METHODS: We conducted immunohistochemistry for MTAP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Carbon Radioisotopes

Share to Isocitrate Dehydrogenase

Share to Methionine

Share to Positron-Emission Tomography

Share to Purine-Nucleoside Phosphorylase

Source

Identifiers

PMID: 38557927
DOI: 10.1007/s11060-024-04661-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of methylthioadenosine phosphorylase immunoreactivity correlates with poor prognosis and elevated uptake of 11C-methionine in IDH-mutant astrocytoma.PMID 38557927Read ↗

Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.Semantic proximity Read ↗

T2-FLAIR mismatch sign, an imaging biomarker for CDKN2A-intact in non-enhancing astrocytoma, IDH-mutant.Semantic proximity Read ↗

Integrated assessment of malignancy in IDH‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistrySemantic proximity Read ↗

Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomasSemantic proximity Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

Methylthioadenosine is Not Dramatically Elevated in <i>MTAP</i> -Homozygous Deleted Primary GlioblastomasSemantic proximity Read ↗

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].Semantic proximity Read ↗

Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study.Semantic proximity Read ↗

T2-FLAIR mismatch sign in nonenhancing astrocytoma, IDH-mutant: impact of tumor area on diagnostic sensitivity.Semantic proximity Read ↗

Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomasSemantic proximity Read ↗

Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.Semantic proximity Read ↗

T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.